MedTrace Logo

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

NCT03367182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-01-11

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (Avastin) added to chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with disease progression within 6 months of platinum treatment.

Conditions

Interventions

DRUG

Weekly paclitaxel

Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle

DRUG

Topotecan

Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle

DRUG

Pegylated liposomal doxorubicin

Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks

DRUG

Bevacizumab

Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03367182 on ClinicalTrials.gov